TNFRSF8 and lymphoma: In the second part of the review, we address how anti‐CD30 therapy was developed and the impact of the anti‐CD30–auristatin conjugate and anti‐CD30 CAR‐T cells in the therapy of CD30‐expressing lymphomas.